In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quadrant Technologies Ltd.

Division of Vectura Group PLC
www.quadrant.co.uk

Latest From Quadrant Technologies Ltd.

Bristol: Rebuilding a Diabetes Franchise--with Insulin

The great remaining religious divide in the drug industry is between those who reject and those who accept the fundamental therapeutic and economic importance of large molecule drugs. Diabetes is the central holy site in the schism since, for the most part, companies have either made small-molecule, oral therapies, or they've made injectable insulin. Bristol-Myers' deals for sustained-release insulin (with Flamel) and inhaled insulin (with QDose) mark both Bristol's increasing embrace of the large-molecule world as well as a novel strategy in the diabetes world.
BioPharmaceutical

Recent Dealmaking (10/2003)

Summarizing the month in European dealmaking.
See All

Company Information

UsernamePublicRestriction

Register